CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating Activities
Net loss	$ (4,510)	$ (3,484)
Adjustments to reconcile net loss to net cash from operating activities:
Depreciation and amortization	5,696	6,484
Amortization of debt issuance costs and Royalty Rights	107	147
Recurring fair value measurements of assets and liabilities	0	9,167
Debt-related expenses	0	9,918
Provisions for inventory and other assets	1,428	1,072
Stock-based compensation	1,207	2,446
Deferred income taxes	0	(1,367)
Changes in assets and liabilities:
Accounts receivable	5,054	(1,109)
Inventories	(2,344)	(3,602)
Prepaid and other assets	1,921	1,824
Accounts payable and other accrued liabilities	(134)	(290)
Accrued rebates, returns and discounts	(267)	2,887
Interest payable	(650)	(1,376)
Net cash provided by operating activities	7,508	22,717
Investing Activities
Purchase of Sympazan	0	(105)
Net cash used in investing activities	0	(105)
Financing Activities
Payments in connection with 2027 Convertible Notes	0	(10,500)
Payment of direct transaction costs related to convertible debt inducement	0	(1,119)
Payment of contingent consideration	0	(6,609)
Payments related to the vesting and settlement of equity awards, net	(206)	(722)
Net cash used in financing activities	(206)	(18,950)
Net increase in cash and cash equivalents	7,302	3,662
Cash and cash equivalents at beginning of year	73,441	64,941
Cash and cash equivalents at end of period	80,743	68,603
Supplemental Disclosure of Cash Flow Information
Net cash paid for income taxes	11	29
Cash paid for interest	$ 1,300	$ 2,351